Property, plant and equipment Financial position and resources Our business is science-based, technology-intensive and highly 2012 regulated by governmental authorities.
We allocate significant 2013 restated m m financial resources to the renewal and maintenance of our property, Assets plant and equipment to minimise risks of interruption of production and to achieve compliance with regulatory standards.
A number of Non-current assets our processes use chemicals and hazardous materials.
Property, plant and equipment 8,872 8,776 Goodwill 4,205 4,359 The total cost of our property, plant and equipment at 31 December Other intangible assets 9,283 10,161 2013 was 18,853 million, with a net book value of 8,872 million.
Of this, land and buildings represented 3,909 million, plant and Investments in associates and joint ventures 323 579 equipment 2,509 million and assets in construction 2,454 million.
Other investments 1,202 787 In 2013, we invested 1,235 million in new and renewal property, Deferred tax assets 2,084 2,391 plant and equipment.
This is mainly related to a large number of Derivative financial instruments 1 54 projects for the renewal, improvement and expansion of facilities Other non-current assets 889 682 at various worldwide sites.
Property is mainly held freehold.
New Total non-current assets 26,859 27,789 investment is financed from our liquid resources.
At 31 December 2013, we had contractual commitments for future capital expenditure Current assets of 443 million and operating lease commitments of 777 million.
Inventories 3,900 3,969 We believe that our facilities are adequate for our current needs.
Current tax recoverable 129 103 We observe stringent procedures and use specialist skills to manage Trade and other receivables 5,442 5,242 environmental risks from our activities.
Environmental issues, Derivative financial instruments 155 49 sometimes dating from operations now modified or discontinued, Liquid investments 66 81 are reported under Our Planet on page 57 and in Note 44 to the Cash and cash equivalents 5,534 4,184 financial statements, Legal proceedings.
Assets held for sale 1 64 Total current assets 15,227 13,692 Goodwill Total assets 42,086 41,481 Goodwill decreased during the year to 4,205 million at December 2013, from 4,359 million.
The decrease primarily reflects a Liabilities weakening of overseas currencies.
Current liabilities Short-term borrowings 2,789 3,631 Other intangible assets Trade and other payables 8,317 8,054 Other intangible assets include the cost of intangibles acquired from Derivative financial instruments 127 63 third parties and computer software.
The net book value of other Current tax payable 1,452 1,374 intangible assets as at 31 December 2013 was 9,283 million 2012 10,161 million.
The decrease in 2013 reflected assets acquired Short-term provisions 992 693 from the acquisition of Okairos AG of 190 million, capitalised Total current liabilities 13,677 13,815 development costs of 246 million and 183 million of computer Non-current liabilities software costs, more than offset by the amortisation and impairment Long-term borrowings 15,456 14,671 of existing intangibles of 682 million and 745 million, respectively.
Deferred tax liabilities 693 1,004 Investments Pensions and other post-employment benefits 2,189 3,121 We held investments, including associates and joint ventures, Other provisions 552 699 with a carrying value at 31 December 2013 of 1,525 million Derivative financial instruments 3 2 2012 1,366 million.
The market value at 31 December 2013 Other non-current liabilities 1,704 1,432 was 2,212 million 2012 1,968 million.
The largest of these Total non-current liabilities 20,597 20,929 investments are in an associate, Aspen Pharmacare Holdings Total liabilities 34,274 34,744 Limited, which had a book value at 31 December 2013 of 229 Net assets 7,812 6,737 million 2012 430 million and an investment in Theravance, Inc. which had a book value at 31 December 2013 of 644 million Equity 2012 362 million.
During the year we sold 28.2 million shares Share capital 1,336 1,349 in Aspen Pharmacare Holdings Limited, representing 6.2% of our Share premium account 2,595 2,022 interest, for 429 million.
The investments include equity stakes in Retained earnings 913 642 companies where the Group has research collaborations, which Other reserves 2,153 1,787 provide access to biotechnology developments of potential interest Shareholders equity 6,997 5,800 and interests in companies that arise from business divestments.
Non-controlling interests 815 937 Total equity 7,812 6,737 GSK Annual Report 2013 69 Strategic report Financial review Net debt decreased by 1,392 million and reflected the receipts Derivative financial instruments: assets of 2.5 billion from the disposals of the Lucozade Ribena and We had both non-current and current derivative financial instruments anti-coagulant products businesses, intangible assets, part of the held at fair value of 156 million 2012 103 million.
The majority Groups investment in Aspen Pharmacare Holdings Limited and of this amount relates to interest rate swaps and foreign exchange other investments.
The impact of these was partly offset by the contracts both designated and non-designated inter-company loans consideration paid to increase the shareholding in the Groups and deposits as accounting hedges.
Indian Consumer Healthcare subsidiary from 43.2% to 72.5% at a Inventories cost of 588 million and to acquire Okarios AG for 205 million.
Inventory of 3,900 million has decreased by 69 million during the The Groups strong cash generation enabled the financing of share year.
The decrease reflects the impact of the disposal of the Lucozade repurchases of 1.5 billion and dividend payments of 3.7 billion.
Ribena and anti-coagulant products businesses partly offset by higher vaccine stocks and stockbuilding for new product launches.
Movements in net debt Trade and other receivables 2013 2012 m m Trade and other receivables of 5,442 million have increased from Net debt at beginning of year 14,037 9,003 2012 reflecting the receivable due from Aspen in respect of the Increase decrease in cash and bank overdrafts 1,473 1,607 inventory and a manufacturing site which formed part of the disposal Cash inflow from liquid investments 15 224 of the anti-coagulants products business partly offset by a weakening Net increase in long-term loans 1,913 4,430 of overseas currencies.
Net repayment of short-term loans 1,872 816 Derivative financial instruments: liabilities Debt of subsidiary undertakings acquired 6 3 We held both non-current and current derivative financial Exchange movements 34 385 instruments at fair value of 130 million 2012 65 million.
Other movements 15 29 This primarily relates to foreign exchange contracts both designated Net debt at end of year 12,645 14,037 and non-designated inter-company loans and deposits, external debt and legal provisions as accounting hedges.
Total equity At 31 December 2013, total equity had increased from 6,737 million Trade and other payables at 31 December 2012 to 7,812 million.
The increase arose principally Trade and other payables amounting to 8,317 million have increased from a reduction in the pension deficit of 699 million, a reduction in from 8,054 million in 2012, reflecting the current year accrual in the post-retirement provision of 439 million and retained profits in respect of the acquisition of further shares in the Groups Indian the year exceeding shares repurchased, partly offset by the liability of Pharmaceutical subsidiary of 635 million partly offset by the effect 635 million arising from the open offer to purchase shares held by of the increased shareholding in the Indian Consumer Healthcare the non-controlling interest in the Groups Indian Pharmaceutical subsidiary accrued in 2012, together with a weakening of overseas subsidiary, GlaxoSmithKline Pharmaceuticals Limited.
A summary of the movements in equity is set out below.
Provisions 2012 We carried deferred tax provisions and other short-term and 2013 restated non-current provisions of 2,237 million at 31 December 2013 m m 2012 2,396 million in respect of estimated future liabilities, of Total equity at beginning of year 6,747 8,827 which 646 million 2012 527 million related to legal and other Prior year adjustment - IAS 19R 10 13 disputes.
Provision has been made for legal and other disputes, At 1 January, as restated 6,737 8,814 indemnified disposal liabilities, employee related liabilities and the Total comprehensive income for the year 6,215 4,014 costs of restructuring programmes to the extent that at the balance Dividends to shareholders 3,680 3,814 sheet date a legal or constructive obligation existed and could be Shares issued 585 356 reliably estimated.
Changes in non-controlling interests 625 218 Pensions and other post-employment benefits Forward contract relating to non-controlling We account for pension and other post-employment arrangements interest 8 in accordance with IAS 19.
The deficits, net of surpluses before Shares purchased and cancelled or held allowing for deferred taxation were 613 million 2012 1,312 as Treasury shares 1,504 2,493 million on pension arrangements and 1,246 million 2012 1,685 Consideration received for shares transferred million on unfunded post-employment liabilities.
by ESOP Trusts 58 In December 2010, the UK scheme purchased an insurance contract Shares acquired by ESOP Trusts 45 37 that will guarantee payment of specified pensioner liabilities.
This Share-based incentive plans 294 211 contract was valued at 775 million at 31 December 2013.
Tax on share-based incentive plans 73 9 Distributions to non-controlling interests 238 171 Net debt Total equity at end of year 7,812 6,737 2013 2012 m m The changes in non-controlling interests in the year primarily arose Cash, cash equivalents and liquid investments 5,600 4,265 from the voluntary open offer to acquire further shares in GSK Borrowings repayable within one year 2,789 3,631 Pharmaceuticals Ltd, the Groups Pharmaceutical subsidiary in India.
Borrowings repayable after one year 15,456 14,671 Net debt 12,645 14,037 70 GSK Annual Report 2013 Commitments in respect of loans and future interest payable on loans Share purchases are disclosed before taking into account the effect of derivatives.
In 2013, the Employee Share Ownership Plan ESOP Trusts acquired 45 million of shares in GlaxoSmithKline plc 2012 We have entered into a number of research collaborations to develop 37 million.
Shares are held by the Trusts to satisfy future exercises new compounds with other pharmaceutical companies.
The terms of of options and awards under the Group share option and award these arrangements can include upfront fees, equity investments, schemes.
A proportion of the shares held by the Trusts are in respect loans and commitments to fund specified levels of research.
In of awards where the rules of the scheme require us to satisfy addition, we will often agree to make further payments if future exercises through market purchases rather than the issue of new milestones are achieved.
The shares held by the Trusts are matched to options and As some of these agreements relate to compounds in the early awards granted.
stages of development, the potential obligation to make milestone At 31 December 2013, the ESOP Trusts held 64 million 2012 payments will continue for a number of years if the compounds move 75 million GSK shares against the future exercise of share options successfully through the development process.
Generally, the closer and share awards.
The carrying value of 355 million 2012 the product is to marketing approval, the greater the possibility of 391 million has been deducted from other reserves.
The amounts shown above within intangible assets value of these shares was 1,025 million 2012 1,004 million.
represent the maximum that would be paid if all milestones were achieved, and include 5.2 billion which relates to externalised During 2013, 92.4 million shares were repurchased at a cost of projects in the discovery portfolio.
A number of new commitments 1,504 million see Note 33 Share capital and share premium were made in 2013 under licensing and other agreements, including account.
We are currently targeting further repurchases of 1-2 arrangements with Adimab LLC, Immunocore Ltd and MorphoSys AG.
The exact amount and timing of future purchases, and whether the shares will be held as Treasury shares or be In 2013, we reached an agreement with the trustees of the UK cancelled, will be determined by the company and is dependent on pension schemes to make additional contributions over a three year market conditions and other factors.
At 31 December 2013, we held period, including in 2013, to eliminate the pension deficit identified 487.4 million shares as Treasury shares 2012 495 million shares, at the 31 December 2011 actuarial funding valuation.
If the deficit at a cost of 6,829 million 2012 6,602 million, which has been persists, further contributions would be payable in the following four deducted from retained earnings.
years depending on the level of deficit.
The table above includes this commitment but excludes the normal ongoing annual funding No shares were purchased in the period 1 January 2014 to 5 requirement in the UK of approximately 120 million.
For further February 2014. information on pension obligations, see Note 28 to the financial Commitments and contingent liabilities statements, Pensions and other post-employment benefits.
Financial commitments are summarised in Note 40 to the financial Contingent liabilities statements, Commitments.
Other contingent liabilities and The following table sets out contingent liabilities, comprising obligations in respect of short and long-term debt are set out in discounted bills, performance guarantees, letters of credit and other Note 31 to the financial statements, Contingent liabilities and items arising in the normal course of business, and when they are Note 32 to the financial statements, Net debt.
Amounts provided for pensions and post-retirement benefits are set out in Note 28 to the financial statements, Pensions and other Total Under 1 yr 1-3 yrs 3-5 yrs 5 yrs m m m m m post-employment benefits.
Amounts provided for restructuring programmes and legal, environmental and other disputes are set out Guarantees 103 75 2 1 25 in Note 29 to the financial statements, Other provisions.
Other contingent liabilities 95 2 27 18 48 Total 198 77 29 19 73 Contractual obligations and commitments The following table sets out our contractual obligations and In the normal course of business, we have provided various commitments at 31 December 2013 as they fall due for payment.
indemnification guarantees in respect of business disposals in which legal and other disputes have subsequently arisen.
A provision Total Under 1 yr 1-3 yrs 3-5 yrs 5 yrs is made where an outflow of resources is considered probable and m m m m m a reliable estimate can be made of the likely outcome of the dispute Loans 18,281 2,747 2,689 3,903 8,942 and this is included in Note 29 to the financial statements, Other Interest on loans 10,063 674 1,244 1,049 7,096 provisions.
Finance lease obligations 80 27 36 12 5 We provide for the outcome of tax, legal and other disputes when an Finance lease charges 7 2 4 1 outflow of resources is considered probable and a reliable estimate Operating lease of the outflow may be made.
At 31 December 2013, other than for commitments 777 134 170 110 363 those disputes where provision has been made, it was not possible Intangible assets 7,056 419 1,107 1,251 4,279 to make a reliable estimate of the potential outflow of funds that might Property, plant & equipment 443 372 69 2 be required to settle disputes where the possibility of there being an Investments 111 29 53 15 14 outflow was more than remote.
Purchase commitments 614 205 261 148 The ultimate liability for such matters may vary significantly from the Pensions 510 85 170 170 85 amounts provided and is dependent upon the outcome of litigation Other commitments 233 75 123 35 proceedings and negotiations with the relevant tax authorities.
This is Total 38,175 4,769 5,926 6,696 20,784 discussed further in Risk factors on pages 232 to 241 and Notes 14 and 44 to the financial statements, Taxation and Legal proceedings.
GSK Annual Report 2013 71 Strategic report Financial review Cash generation and conversion Investment appraisal A summary of the consolidated cash flow is set out below.
We have a formal process for assessing potential investment proposals in order to ensure decisions are aligned with our overall 2013 2012 strategy.
This process includes an assessment of the cash flow return m m on investment CFROI, as well as its net present value NPV and Net cash inflow from operating activities 7,222 4,375 internal rate of return IRR where the timeline for the project is very Net cash inflow outflow from investing activities 524 2,631 long term.
We also consider the impact on earnings and credit profile Net cash outflow from financing activities 6,273 3,351 where relevant.
Increase decrease in cash and bank overdrafts 1,473 1,607 The discount rate used to perform financial analyses is decided Cash and bank overdrafts at beginning of year 3,906 5,605 internally, to allow determination of the extent to which investments cover our cost of capital.
For specific investments the discount rate Increase decrease in cash and bank overdrafts 1,473 1,607 may be adjusted to take into account country or other risk weightings.
Exchange adjustments 148 92 Cash and bank overdrafts at end of year 5,231 3,906 Capital expenditure and financial investment Cash payments for tangible and intangible fixed assets amounted Cash and bank overdrafts at end of year to 1,701 million 2012 - 1,520 million and disposals realised comprise: 2,033 million 2012 1,124 million.
Cash payments to acquire Cash and cash equivalents 5,534 4,184 equity investments of 133 million 2012 229 million were made Overdrafts 303 278 in the year and sales of equity investments realised 59 million 5,231 3,906 2012 28 million.
The net cash inflow from operating activities for the year was 7,222 Future cash flow million 2012 4,374 million.
The increase primarily reflected legal We expect that future operating cash flow will be sufficient to fund settlements being some 2.5 billion lower than in 2012, together with our operating and debt service costs, to satisfy normal levels of the phasing of restructuring expenditure, lower tax payments and capital expenditure, to meet obligations under existing licensing pension contributions, partially offset by a smaller reduction in agreements, to meet the expenditure arising from the major working capital compared with 2012 given supply chain investments restructuring programmes the precise timing of which is uncertain in inventory and launch preparation.
outlined in Note 10 to the financial statements, Major restructuring costs and to meet other routine outflows including tax and dividends, Free cash flow subject to the Risk factors discussed on pages 232 to 241.
We may Free cash flow is the amount of cash generated by the business after from time to time have additional demands for finance, such as for meeting our obligations for interest, tax and dividends paid to acquisitions and share repurchases.
We have access to other non-controlling interests, and after capital expenditure on property, sources of liquidity from short and long-term capital markets and plant and equipment and intangible assets.
banks and other financial institutions, in addition to the cash flow 2013 2012 from operations, for such needs.
Free cash flow m 4,657 2,049 Working capital Free cash flow growth % 100% 51 % 2013 2012 Free cash flow was 4,657 million for the year.
The increase on 2012 Working capital percentage of turnover % 19% 21% primarily reflected the impact of lower tax payments and special UK Working capital conversion cycle days 176 194 pension contributions, partly offset by a smaller reduction in working capital and increased expenditure on property, plant and equipment.
Our working capital programme has continued to make progress We paid dividends to shareholders of 3,680 million, and spent with further improvements in the collection of receivables and more 1,504 million on repurchasing shares.
effective management of payables balances.
During the year a A reconciliation of net cash inflow from operating activities, which is the number of initiatives were implemented across our supply chains closest equivalent IFRS measure, to free cash flow is shown below.
supporting the Pharmaceutical, Vaccines and Consumer Healthcare businesses that have provided stronger end-to-end accountability in Reconciliation of free cash flow each case.
These programmes are at an early stage but have already 2013 2012 reduced volatility and improved responsiveness allowing better m m inventory management.
The net impact on inventory has been limited Net cash inflow from operating activities 7,222 4,375 in 2013 as significant investments have also been made in improving Purchase of property, plant and equipment 1,188 1,051 service levels and preparing for new product launches.
Purchase of intangible assets 513 469 The reported working capital conversion cycle days are distorted Disposal of property, plant and equipment 46 68 by divestments made during the year and the intangible asset Interest paid 749 779 impairments included in the denominator used in the conversion Interest received 59 30 cycle computation.
The year-end 2013 and 2012 conversion cycles, Dividends received from joint ventures and adjusted for these factors, were around 190 days and around 200 associated undertakings 18 46 days, respectively, a reduction of 10 days.
Distributions to non-controlling interests 238 171 Free cash flow 4,657 2,049 72 GSK Annual Report 2013 Maturity profile of gross debt Maturity prole of gross debt m equivalent 3,000 2,500 2,000 1,500 1,000 500 0 2014 2015 2016 2017 2018 2022 2023 2025 2027 2033 2034 2038 2039 2042 2043 2045 GBP bonds EUR bonds USD bonds Commercial Paper Other bank borrowings Leases Treasury policies Liquidity GSK reports in Sterling and pays dividends out of sterling profits.
As at 31 December 2013, our cash and liquid investments were held The role of Corporate Treasury is to monitor and manage our external as follows: and internal funding requirements and financial risks in support of our 2013 2012 strategic objectives.
GSK operates on a global basis, primarily through m m subsidiary companies, and we manage our capital to ensure that our Bank balances and deposits 4,641 3,456 subsidiaries are able to operate as going concerns and to optimise US Treasury and Treasury repo returns to shareholders through an appropriate balance of debt and only money market funds 893 728 equity.
Treasury activities are governed by policies approved by the Corporate debt instruments 1 7 Board of Directors, most recently on 9 July 2013.
A Treasury Government securities 65 74 Management Group TMG meeting chaired by our Chief Financial Officer, takes place on a monthly basis to review treasury activities.
5,600 4,265 Its members receive management information relating to treasury Cash and liquid investments of 3.9 billion, including amounts held by activities.
ViiV Healthcare, were held centrally at 31 December 2013.
Capital management We had net debt of 12.6 billion at 31 December 2013.
The table below Our financial strategy supports the Groups strategic priorities and summarises cash and gross debt after the effects of hedging.
it is regularly reviewed by the Board.
We manage the capital structure of the Group through an appropriate mix of debt and equity.
2013 2012 m m GSKs financial architecture is designed to support the delivery of Cash and liquid investments 5,600 4,265 the Groups strategy, and to enhance returns to shareholders.
There Gross debt fixed 15,593 15,205 are four key priorities: delivering sustainable sales growth, improving floating 2,651 3,090 operating leverage, improving financial efficiency and converting non-interest bearing 1 7 more of our earnings into cash.
The free cash flow generated can Net debt 12,645 14,037 then be returned to shareholders or reinvested in bolt-on acquisitions, wherever the most attractive returns are available.
GSK continues GSKs policy is to borrow centrally in order to meet anticipated to apply strict financial and returns-based criteria such as cash funding requirements.
The cash flow forecast and funding flow return on investment in order to allocate capital and assess requirements are monitored by the TMG on a monthly basis.
investment opportunities, whilst protecting its credit profile.
Our strategy is to diversify liquidity sources using a range of The business remains highly cash generative and in 2013 GSK facilities and to maintain broad access to funding markets.
generated 4.7 billion in free cash flow.
In addition, we realised GSKs long-term credit ratings have remained unchanged since 2.5 billion from divestments.
In 2013, we returned a total of February 2008.
Our current ratings are A stable outlook by 5.2 billion to shareholders, 3.7 billion in dividends and Standard and Poors and A1 negative outlook by Moodys Investors 1.5 billion in share repurchases.
Net debt at the end of the Service Moodys.
Our short-term credit ratings are A-1 and P-1 year stood at 12.6 billion, a reduction of 1.4 billion compared with Standard and Poors and Moodys respectively.
In 2014, we expect to deliver continued dividend growth and as part of the long-term share buyback programme are targeting share repurchases of 1-2 billion depending on market conditions.
For further details see Note 41 to the financial statements Financial instruments and related disclosures.
